Article

A Clinician-Driven Automated System for Integration of Pharmacogenetic Interpretations Into an Electronic Medical Record

Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Clinical Pharmacology &#38 Therapeutics (Impact Factor: 7.39). 09/2012; 92(5):563-6. DOI: 10.1038/clpt.2012.140
Source: PubMed

ABSTRACT Advances in pharmacogenetic testing will expand the number of clinically important pharmacogenetic variants. Communication and interpretation of these test results are critical steps in implementation of pharmacogenetics into the clinic. Computational tools that integrate directly into the electronic medical record (EMR) are needed to translate the growing number of genetic variants into interpretive consultations to facilitate gene-based drug prescribing. Herein, we describe processes for incorporating pharmacogenetic tests and interpretations into the EMR for clinical practice.Clinical Pharmacology & Therapeutics (2012); advance online publication 19 September 2012. doi:10.1038/clpt.2012.140.

Full-text

Available from: Cyrine E Haidar, Jan 06, 2014
1 Follower
 · 
170 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Whole genome sequence (WGS) information may soon be widely available to help clinicians personalize the care and treatment of patients. However, considerable barriers exist, which may hinder the effective utilization of WGS information in a routine clinical care setting. Clinical decision support (CDS) offers a potential solution to overcome such barriers and to facilitate the effective use of WGS information in the clinic. However, genomic information is complex and will require significant considerations when developing CDS capabilities. As such, this manuscript lays out a conceptual framework for a CDS architecture designed to deliver WGS-guided CDS within the clinical workflow. To handle the complexity and breadth of WGS information, the proposed CDS framework leverages service-oriented capabilities and orchestrates the interaction of several independently-managed components. These independently-managed components include the genome variant knowledge base, the genome database, the CDS knowledge base, a CDS controller and the electronic health record (EHR). A key design feature is that genome data can be stored separately from the EHR. This paper describes in detail: (1) each component of the architecture; (2) the interaction of the components; and (3) how the architecture attempts to overcome the challenges associated with WGS information. We believe that service-oriented CDS capabilities will be essential to using WGS information for personalized medicine.
    02/2014; 4(2):176-199. DOI:10.3390/jpm4020176
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the past 10 years, electronic health records (EHRs) have had growing impact in clinical care. EHRs efficiently capture and reuse clinical information, which can directly benefit patient care by guiding treatments and providing effective reminders for best practices. The increased adoption has also lead to more complex implementations, including robust, disease-specific tools, such as for rheumatoid arthritis (RA). In addition, the data collected through normal clinical care is also used in secondary research, helping to refine patient treatment for the future. Although few studies have directly demonstrated benefits for direct clinical care of RA, the opposite is true for EHR-based research - RA has been a particularly fertile ground for clinical and genomic research that have leveraged typically advanced informatics methods to accurately define RA populations. We discuss the clinical impact of EHRs in RA treatment and their impact on secondary research, and provide recommendations for improved utility in future EHR installations.
    Expert Review of Clinical Immunology 02/2015; 11(3):1-9. DOI:10.1586/1744666X.2015.1009895 · 3.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Clinicians already face “personalized” medicine every day while experiencing the great variation in toxicities and drug efficacy between individual patients. Pharmacogenetic studies are the platform for discovering the DNA determinants of that variability in drug response and tolerability. Research now focuses on the genome after its beginning with analyses of single genes. Therapeutic outcomes from several psychotropic drugs have been weakly linked to specific genetic variants, and without independent replication. Drug side effects show stronger associations to genetic variants, including HLA loci with carbamazepine-induced dermatologic outcome and MC4R with atypical antipsychotic weight gain. Clinical implementation has proven challenging, with barriers including a lack of replicable prospective evidence for clinical utility required for altering medical care. Recent studies show promising approaches for reducing these barriers to routine incorporation of pharmacogenetic data into clinical care.
    Biological Psychiatry 01/2014; 77(1). DOI:10.1016/j.biopsych.2014.09.009 · 9.47 Impact Factor